Trial · NCT04711603
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Period (6 Weeks) | STARTED | Double Blind Period: MR13A9 0.5 μg/kg Group | 89 | |
| Double-blind Period (6 Weeks) | STARTED | Double Blind Period: Placebo Group | 89 | |
| Double-blind Period (6 Weeks) | STARTED | Entire Study: MR13A9/MR13A9 Group | 0 | |
| Double-blind Period (6 Weeks) | STARTED | Entire Study: Placebo/MR13A9 Group | 0 | |
| Double-blind Period (6 Weeks) | COMPLETED | Double Blind Period: MR13A9 0.5 μg/kg Group | 85 | |
| Double-blind Period (6 Weeks) | COMPLETED | Double Blind Period: Placebo Group | 83 | |
| Double-blind Period (6 Weeks) | COMPLETED | Entire Study: MR13A9/MR13A9 Group | 0 | |
| Double-blind Period (6 Weeks) | COMPLETED | Entire Study: Placebo/MR13A9 Group | 0 | |
| Double-blind Period (6 Weeks) | NOT COMPLETED | Double Blind Period: MR13A9 0.5 μg/kg Group | 4 | |
| Double-blind Period (6 Weeks) | NOT COMPLETED | Double Blind Period: Placebo Group | 6 | |
| Double-blind Period (6 Weeks) | NOT COMPLETED | Entire Study: MR13A9/MR13A9 Group | 0 | |
| Double-blind Period (6 Weeks) | NOT COMPLETED | Entire Study: Placebo/MR13A9 Group | 0 | |
| Extension Period (52 Weeks) | STARTED | Double Blind Period: MR13A9 0.5 μg/kg Group | 0 | |
| Extension Period (52 Weeks) | STARTED | Double Blind Period: Placebo Group | 0 | |
| Extension Period (52 Weeks) | STARTED | Entire Study: MR13A9/MR13A9 Group | 85 | |
| Extension Period (52 Weeks) | STARTED | Entire Study: Placebo/MR13A9 Group | 83 | |
| Extension Period (52 Weeks) | COMPLETED | Double Blind Period: MR13A9 0.5 μg/kg Group | 0 | |
| Extension Period (52 Weeks) | COMPLETED | Double Blind Period: Placebo Group | 0 | |
| Extension Period (52 Weeks) | COMPLETED | Entire Study: MR13A9/MR13A9 Group | 68 | |
| Extension Period (52 Weeks) | COMPLETED | Entire Study: Placebo/MR13A9 Group | 54 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04711603/flow